Sai Life Sciences CFO discussed the company's shift from near-zero Big Pharma exposure in FY20 to 40% today in its discovery business, and rising China Plus One-driven diversification by large pharma to India

Wed 30 Sep 2026

Discovery business pharma share now

40 percent

Discovery business pharma share FY20

0 percent (implied)

Discovery share of total revenue

35 percent

Heard on Live TV News Channel between 09:33:52 - 09:35:07 IST.

• CFO Chittor confirmed a Jefferies report finding of zero Big Pharma exposure in the discovery/CRO business by FY20, now moved to 40% pharma, 60% biotech.
• Clarified discovery is 35% of total company revenues, up about 10 percentage points from roughly 1.5 years ago.
• Said CDMO business has historically been pharma-weighted, while discovery/CRO was biotech-focused, now diversifying.
• Attributed the shift to building discovery infrastructure post-2020 and large pharma companies increasingly moving work to India amid China Plus One trend.
• On AI in drug discovery, said gap remains in translating AI-designed molecules to clinic; synthesis and regulatory approval still required, so business model not fundamentally changed yet, though company is adopting AI internally to improve scientist productivity.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.